Decibel Therapeutics, Inc.
DBTXDelisted Sep 25, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001656536
Decibel Therapeutics, Inc. was delisted on Sep 25, 2023; its insiders filed their last Form 4 on Sep 25, 2023; 37 institutions reported holding it in 13F filings for Q2 2023, worth $59.2M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 37
- Q2 2023, −1 vs. previous quarter
- 13F value
- $59.2M
- Reported value at the end of Q2 2023
- Superinvestors holding
- 0
- At the end of Q2 2023
Superinvestors holding DBTX, Q2 2023
No superinvestor reported holding DBTX at the end of Q2 2023.
Latest insider trades
Open-market purchases and sales by Decibel Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 4, 2022 (view filing) | Jan 3 | 1 day | Trask AnnaSee Remarks | SSale | −378 | $5.03 | −$1.90K | −16.9%1.86K after | 2 lots |
| Dec 6, 2021 (view filing) | Dec 2 | 4 days | Trask AnnaSee Remarks | SSale | −5.29K | $6.37 | −$33.7K | −70.2%2.24K after | 2 lots |
| Nov 4, 2021 (view filing) | Nov 3 | 1 day | Trask AnnaSee Remarks | SSale | −378 | $8.34 | −$3.15K | −4.8%7.53K after | |
| Nov 3, 2021 (view filing) | Nov 2 | 1 day | Trask AnnaSEE REMARKS | SSale | −4.91K | $8.31 | −$40.8K | −38.3%7.91K after | |
| Oct 15, 2021 (view filing) | Oct 14 | 1 day | Trask AnnaSee Remarks | SSale | −5.36K | $7.55 | −$40.5K | −29.5%12.8K after | |
| Sep 17, 2021 (view filing) | Sep 15 | 2 days | Reid LaurencePresident and Chief Executive | PPurchase | +10.0K | $7.64 | +$76.4K | +63.1%25.8K after |
Top 10 13F holders, Q2 2023
The largest institutional positions in Decibel Therapeutics, Inc. at the end of Q2 2023; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| OrbiMed Advisors LLC | 4,945,192 | $19.0M | 0.37% | 00.0% | Unchanged |
| TRV GP III, LLC | 3,139,685 | $12.1M | 66.29% | 00.0% | Unchanged |
| BlackRock Inc. | 1,811,483 | $6.97M | 0.00% | +5,337+0.3% | Added |
| Alphabet Inc. | 1,636,258 | $6.30M | 0.34% | 00.0% | Unchanged |
| Samsara BioCapital, LLC | 801,629 | $3.09M | 0.54% | 00.0% | Unchanged |
| Vanguard Group Inc | 642,325 | $2.47M | 0.00% | 00.0% | Unchanged |
| Bessemer Group Inc | 494,071 | $1.90M | 0.00% | 00.0% | Unchanged |
| Harvard Management Co Inc | 326,029 | $1.25M | 0.12% | −2,769−0.8% | Reduced |
| Newtyn Management, LLC | 200,000 | $770.0K | 0.18% | −53,818−21.2% | Reduced |
| UBS Oconnor LLC | 199,200 | $766.9K | 0.02% | +9,814+5.2% | Added |